↓ Skip to main content

Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management

Overview of attention for book
Attention for Chapter 2: Emerging Biomarkers in Personalized Therapy of Lung Cancer
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Emerging Biomarkers in Personalized Therapy of Lung Cancer
Chapter number 2
Book title
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Published in
Advances in experimental medicine and biology, December 2015
DOI 10.1007/978-3-319-24932-2_2
Pubmed ID
Book ISBNs
978-3-31-924931-5, 978-3-31-924932-2
Authors

Philip T. Cagle, Kirtee Raparia, Bryce P. Portier, Cagle, Philip T, Raparia, Kirtee, Portier, Bryce P, Philip T. Cagle M.D., Kirtee Raparia M.D., Bryce P. Portier M.D., Ph.D., Cagle, Philip T., Portier, Bryce P.

Editors

Aamir Ahmad, Shirish M. Gadgeel

Abstract

The two clinically validated and Food and Drug Administration approved lung cancer predictive biomarkers (epidermal growth factor receptor mutations and anaplastic lymphoma kinase (ALK) translocations) occur in only about 20 % of lung adenocarcinomas and acquired resistance develops to first generation drugs. Several other oncogenic drivers for lung adenocarcinoma have emerged as potentially druggable targets with new predictive biomarkers. Oncologists are requesting testing for ROS1 translocations which predict susceptibility to crizotinib, already approved for ALK positive lung cancers. Other potential biomarkers which are currently undergoing clinical trials are RET, MET, HER2 and BRAF. Detection of these biomarkers includes fluorescent in situ hybridization and/or reverse transcriptase polymerase chain reaction (ROS1, RET, HER2), mutation analysis (BRAF) and immunohistochemistry (MET). Screening by immunohistochemistry may be useful for some biomarkers (ROS1, BRAF). Targeted next generation sequencing techniques may be useful as well. These five biomarkers are under consideration for inclusion in revised lung cancer biomarker guidelines by the College of American Pathologists, International Association for the Study of Lung Cancer and Association for Molecular Pathology.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 5%
United States 1 5%
Unknown 18 90%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 25%
Student > Postgraduate 3 15%
Student > Ph. D. Student 2 10%
Professor 2 10%
Student > Master 2 10%
Other 3 15%
Unknown 3 15%
Readers by discipline Count As %
Medicine and Dentistry 9 45%
Agricultural and Biological Sciences 4 20%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Neuroscience 1 5%
Other 0 0%
Unknown 4 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2016.
All research outputs
#4,245,701
of 9,678,652 outputs
Outputs from Advances in experimental medicine and biology
#857
of 2,906 outputs
Outputs of similar age
#111,539
of 326,269 outputs
Outputs of similar age from Advances in experimental medicine and biology
#151
of 668 outputs
Altmetric has tracked 9,678,652 research outputs across all sources so far. This one has received more attention than most of these and is in the 55th percentile.
So far Altmetric has tracked 2,906 research outputs from this source. They receive a mean Attention Score of 3.4. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,269 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 668 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.